KRYSTEXXA
sUA STOPPING
RULES

The KRYSTEXXA sUA Stopping Rules were designed to help avoid infusion reactions

The rules were developed after a post hoc analysis of the pivotal clinical trials. Data showed a correlation between the preinfusion sUA level rising above 6 mg/dL and the occurrence of infusion reactions for patients already on KRYSTEXXA.[1]

FOR USE AFTER
FIRST INFUSION

Take a preinfusion sUA measurement, preferably within 48 hours prior to each infusion.[1]



If the preinfusion sUA level is ≤6 mg/dL, then treatment can be continued.[1]

If the preinfusion sUA level is >6 mg/dL, consider discontinuing treatment, particularly when 2 consecutive sUA levels >6 mg/dL are observed.[1]

- Appropriate patients should be premedicated with antihistamines and corticosteroids[1]
- Patients should discontinue oral urate-lowering agents while taking KRYSTEXXA[1]

INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA.

Please see Important Safety Information on following page and click for Prescribing Information, including Boxed Warning, and Medication Guide.

KRYSTEXXA®
pegloticase